Glaukos (NYSE:GKOS) Price Target Raised to $226.00

Glaukos (NYSE:GKOS) had its target price raised by equities researchers at Wells Fargo & Company from $178.00 to $226.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective indicates a potential downside of 1.14% from the stock’s current price.

A number of other analysts also recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $240.00 price objective (up from $195.00) on shares of Glaukos in a report on Thursday. HC Wainwright lifted their price target on shares of Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC boosted their price target on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday. BTIG Research increased their price target on Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Truist Financial set a $255.00 price target on Glaukos in a research report on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $201.57.

Glaukos Stock Performance

NYSE GKOS traded up $47.18 during trading on Thursday, reaching $228.61. 1,241,936 shares of the company’s stock were exchanged, compared to its average volume of 876,878. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The stock has a market capitalization of $13.48 billion, a P/E ratio of -70.02 and a beta of 0.69. Glaukos has a fifty-two week low of $80.90 and a fifty-two week high of $229.27. The business has a 50 day moving average price of $171.24 and a 200-day moving average price of $139.87.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million during the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company’s revenue for the quarter was up 58.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) earnings per share. Sell-side analysts forecast that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Alex Thurman sold 20,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares in the company, valued at $7,908,787.78. This represents a 31.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at $13,046,967.12. This trade represents a 45.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 83,025 shares of company stock worth $14,950,006 over the last 90 days. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Glaukos

A number of hedge funds have recently modified their holdings of the business. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Glaukos in the 3rd quarter valued at about $1,248,000. Vise Technologies Inc. bought a new position in shares of Glaukos during the third quarter worth about $668,000. State of Wyoming raised its position in shares of Glaukos by 6.8% during the third quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock worth $169,000 after acquiring an additional 66 shares during the last quarter. Choreo LLC raised its position in shares of Glaukos by 4.0% during the third quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier’s stock worth $582,000 after acquiring an additional 136 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its stake in shares of Glaukos by 35.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 2,172 shares of the medical instruments supplier’s stock worth $357,000 after acquiring an additional 570 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record growth and profitability: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the $168 million analyst consensus. Glaukos reported adjusted EPS of $0.47 versus expectations for a $0.10 loss, while GAAP results showed $2 million in net income, or $0.03 per diluted share, compared with a loss in the prior-year quarter. Glaukos Q3 earnings and revenue report
• Positive Sentiment: Higher sales outlook: Management raised 2026 revenue guidance to $775 million-$785 million from $680 million-$700 million and introduced a preliminary 2027 sales target of approximately $1 billion. The outlook reflects continued momentum in the company’s glaucoma and corneal-health franchises, including iDose TR and Epioxa. Glaukos strong Q3 results and higher sales outlook
• Positive Sentiment: Analysts raised targets and ratings: Needham lifted its target to $251, BTIG raised its target to $234, and Stifel increased its target to $225; all three firms now rate GKOS “Buy.” The new targets imply meaningful upside from the stock’s recent trading level. Needham analyst ratings
• Positive Sentiment: Healthy financial position: Glaukos generated $14.8 million in operating cash flow and ended the quarter with $162.3 million in cash, supporting continued investment in product development and commercialization.
• Neutral Sentiment: The earnings call and financial releases will be closely watched for additional details on adoption, reimbursement, and the pace at which iDose TR and Epioxa can support the ambitious 2027 sales target. Glaukos Q3 earnings call transcript
• Negative Sentiment: Quiver data shows 32 open-market insider sales and no purchases over the past six months, including selling by senior executives. While such transactions may reflect compensation or diversification, the pattern is a potential secondary concern for investors.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.